920796-73-2Relevant academic research and scientific papers
NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS
-
, (2013/08/15)
The present invention provides compounds of Formula I or a pharmaceutical salt thereof, methods of treating hypertriglyceridemia using the compounds; and a process for preparing the compounds.
2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors
Fukunaga, Kenji,Uehara, Fumiaki,Aritomo, Keiichi,Shoda, Aya,Hiki, Shinsuke,Okuyama, Masahiro,Usui, Yoshihiro,Watanabe, Kazutoshi,Yamakoshi, Koichi,Kohara, Toshiyuki,Hanano, Tokushi,Tanaka, Hiroshi,Tsuchiya, Susumu,Sunada, Shinji,Saito, Ken-Ichi,Eguchi, Jun-Ichi,Yuki, Satoshi,Asano, Shoichi,Tanaka, Shinji,Mori, Akiko,Yamagami, Keiji,Baba, Hiroshi,Horikawa, Takashi,Fujimura, Masatake
, p. 6933 - 6937 (2014/01/06)
A series of 2-(2-phenylmorpholin-4-yl)pyrimidin-4(3H)-ones was synthesized and examined for their inhibitory activity against glycogen synthase kinase-3β (GSK-3β). We found 21, 29 and 30 to possess potent in vitro GSK-3β inhibitory activity with good in vitro PK profiles. 21 demonstrated significant decrease of tau phosphorylation after oral administration in mice and excellent PK profiles.
INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF
-
Page/Page column 81-82, (2008/06/13)
The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invention also relates t
